Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimo Dietrich

Showing results (51-60 of 116) with videos related to

Pageof 12
Sort By:
The Journal of Molecular Diagnostics : JMD|December 13, 2016
PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core BiopsiesBarbara Uhl, Heidrun Gevensleben, Yuri Tolkach, et al.
Clinical Chemistry|January 11, 2019
Cell-Free <i>SHOX2</i> DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort StudyMaria Jung, Jörg Ellinger, Heidrun Gevensleben, et al.
Oncotarget|July 28, 2016
CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patientsDiane Goltz, Emily Eva Holmes, Heidrun Gevensleben, et al.
Oncotarget|February 9, 2018
<i>PD-L1</i> (<i>CD274</i>) and <i>PD-L2</i> (<i>PDCD1LG2</i>) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomasAlina Franzen, Timo J Vogt, Tim Müller, et al.
Biological Chemistry|August 27, 2021
Identification of cytokeratin24 as a tumor suppressor for the management of head and neck cancerDésirée Gül, Negusse Habtemichael, Dimo Dietrich, et al.
Clinical Epigenetics|October 7, 2016
<i>PITX3</i> promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomyEmily Eva Holmes, Diane Goltz, Verena Sailer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 4, 2021
Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast CancerDamian J Ralser, Niklas Klümper, Heidrun Gevensleben, et al.
Clinical Epigenetics|February 9, 2017
<i>PITX3</i> DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinomaVerena Sailer, Emily Eva Holmes, Heidrun Gevensleben, et al.
Oncotarget|May 11, 2017
PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patientsDiane Goltz, Heidrun Gevensleben, Joern Dietrich, et al.
British Journal of Cancer|April 4, 2018
Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort studyJulia Bergheim, Alexander Semaan, Heidrun Gevensleben, et al.
Pageof 12

Showing results (51-60 of 116) with videos related to

Sort By:
Pageof 12
The Journal of Molecular Diagnostics : JMD|December 13, 2016
PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core BiopsiesBarbara Uhl, Heidrun Gevensleben, Yuri Tolkach, et al.
Clinical Chemistry|January 11, 2019
Cell-Free <i>SHOX2</i> DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort StudyMaria Jung, Jörg Ellinger, Heidrun Gevensleben, et al.
Oncotarget|July 28, 2016
CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patientsDiane Goltz, Emily Eva Holmes, Heidrun Gevensleben, et al.
Oncotarget|February 9, 2018
<i>PD-L1</i> (<i>CD274</i>) and <i>PD-L2</i> (<i>PDCD1LG2</i>) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomasAlina Franzen, Timo J Vogt, Tim Müller, et al.
Biological Chemistry|August 27, 2021
Identification of cytokeratin24 as a tumor suppressor for the management of head and neck cancerDésirée Gül, Negusse Habtemichael, Dimo Dietrich, et al.
Clinical Epigenetics|October 7, 2016
<i>PITX3</i> promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomyEmily Eva Holmes, Diane Goltz, Verena Sailer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 4, 2021
Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast CancerDamian J Ralser, Niklas Klümper, Heidrun Gevensleben, et al.
Clinical Epigenetics|February 9, 2017
<i>PITX3</i> DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinomaVerena Sailer, Emily Eva Holmes, Heidrun Gevensleben, et al.
Oncotarget|May 11, 2017
PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patientsDiane Goltz, Heidrun Gevensleben, Joern Dietrich, et al.
British Journal of Cancer|April 4, 2018
Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort studyJulia Bergheim, Alexander Semaan, Heidrun Gevensleben, et al.
Pageof 12